Shareholder Votes

Willdan Group, Inc. shareholders approved Approval of the amendments to the 2008 Plan at the 2026-06-17 meeting.

“Proposal 4 Approval of the amendments to the 2008 Plan. For Against Abstain Broker Non-Vote 7,934,725 ​ 1,138,027 ​ 204,543 ​ 2,682,651”

Willdan Group, Inc. shareholders approved Approval, on a non-binding advisory basis, of the Company's named executive officer compensation at the 2026-06-17 meeting.

“Proposal 3 Approval, on a non-binding advisory basis, of the Company’s named executive officer compensation. For Against Abstain Broker Non-Vote 8,650,776 ​ 409,216 ​ 217,303 ​ 2,682,651”

Willdan Group, Inc. shareholders approved Ratification of the Board's appointment of Crowe as the Company's independent registered public accounting firm for fiscal year 2026 at the 2026-06-17 meeting.

“Proposal 2 Ratification of the Board’s appointment of Crowe as the Company’s independent registered public accounting firm for fiscal year 2026. ​ For Against Abstain 11,780,234 ​ 151,378 ​ 28,334”

Willdan Group, Inc. shareholders approved Elect the seven director nominees named in the Proxy Statement at the 2026-06-17 meeting.

“Proposal 1 Each individual listed below was elected to serve on the Board until the 2026 annual meeting of stockholders and until his or her respective successor is duly elected and qualified, or until his or her earlier death, resignation or removal. For Withheld Broker Non-Vote Thomas D. Brisbin 8,839,288 ​ 438,007 ​ 2,682,651 Michael A. Bieber ​ 9,099,674 ​ 177,621 ​ 2,682,651 ​ Steven A. Cohen ​ 8,918,743 ​ 358,552 ​ 2,682,651 ​ Cynthia A. Downes 9,226,015 ​ 51,280 ​ 2,682,651 Dennis V. McGinn 8,991,602 ​ 285,693 ​ 2,682,651 ​ Wanda K. Reder ​ 9,005,915 ​ 271,380 ​ 2,682,651 ​ Mohammad Shahidehpour ​ 8,384,196 ​ 893,099 ​ 2,682,651”

SAB Biotherapeutics, Inc. shareholders approved Ratify the appointment of EisnerAmper LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026 at the 2026-06-18 meeting.

“Proposal 2: Ratification of the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 Votes For Votes Against Abstentions 59,319,363 3,373 26,798”

SAB Biotherapeutics, Inc. shareholders approved Election of Dr. David Zaccardelli, Pharm.D., Katie Ellias, David Link, MBA, and Andrew Moin, as Class II directors to serve for a term of three years at the 2026-06-18 meeting.

“Proposal 1 : Election of four Class II directors Director Votes For Withheld Broker Non-Votes David Zaccardelli, Pharm.D. 48,352,114 2,984 10,994,436 David Link, MBA 44,083,923 4,271,175 10,994,436 Katie Ellias 48,350,086 5,012 10,994,436 Andrew Moin 44,157,704 4,197,394 10,994,436”

SharkNinja, Inc. shareholders approved Amendment and Restatement of the Company's Amended and Restated Memorandum and Articles of Association at the 2026-06-18 meeting.

“5. Shareholders approved an Amendment and Restatement of the Company’s Amended and Restated Memorandum and Articles of Association. The voting results were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTE 124,285,821 448,385 45,403 10,048,799”

SharkNinja, Inc. shareholders approved Non-binding advisory vote on frequency of future advisory votes on executive compensation at the 2026-06-18 meeting.

“4. Shareholders selected, on a non-binding advisory basis, the frequency of future advisory votes on the compensation of our named executive officers as “One Year”. The voting results were as follows: ONE YEAR TWO YEARS THREE YEARS ABSTAIN BROKER NON-VOTE 123,853,354 205,886 639,475 80,894 10,048,799”

SharkNinja, Inc. shareholders approved Non-binding advisory vote on compensation of named executive officers at the 2026-06-18 meeting.

“3. Shareholders approved, on a non-binding advisory basis, the compensation of our named executive officers. The voting results were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTE 115,503,073 9,231,410 45,126 10,048,799”

SharkNinja, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered accounting firm for fiscal year ending December 31, 2026 at the 2026-06-18 meeting.

“2. Shareholders ratified the appointment of Ernst & Young LLP as the independent registered accounting firm of the Company for the fiscal year ending December 31, 2026. The voting results were as follows: FOR AGAINST ABSTAIN 134,155,878 37,480 635,050”

SharkNinja, Inc. shareholders approved Election of seven directors at the 2026-06-18 meeting.

“1. Shareholders re-appointed all of the seven nominees for directors, in each case to hold office in accordance with the Company’s Amended and Restated Memorandum and Articles of Association. The voting results were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTE Mark Barrocas 123,533,281 1,174,449 71,879 10,048,799 Kathryn J. Barton 120,251,450 4,456,602 71,557 10,048,799 Peter Feld 123,888,797 818,633 72,179 10,048,799 Chi Kin Max Hui 98,131,389 26,564,567 83,653 10,048,799 Barney Tianhao Wang 123,177,599 1,529,963 72,047 10,048,799 Timothy R. Warner 104,937,676 19,757,587 84,346 10,048,799 Jason M. Wortendyke 123,859,380 847,496 72,733 10,048,799”

Protagonist Therapeutics, Inc shareholders approved Approval of the adoption of the Company’s 2026 Equity Incentive Plan.

“Proposal 4 — To approve the adoption of the Company’s 2026 Equity Incentive Plan. This proposal was approved by the requisite vote, with the votes thereon as follows: Final Voting Results For Against Abstentions Broker Non-Votes 47,745,562 8,826,703 17,748 2,819,234”

Protagonist Therapeutics, Inc shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-12-31 meeting.

“Proposal 3 — To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2026. This proposal was approved by the requisite vote, with the votes thereon as follows: Final Voting Results For Against Abstentions Broker Non-Votes 59,371,487 28,221 9,539 —”

Protagonist Therapeutics, Inc shareholders approved Approval, on a non-binding advisory basis, of the compensation of the named executive officers.

“Proposal 2 — To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers. This proposal was approved by the requisite vote, with the votes thereon as follows: Final Voting Results For Against Abstentions Broker Non-Votes 53,412,559 3,164,702 12,752 2,819,234”

Protagonist Therapeutics, Inc shareholders approved Election of two Class I director nominees.

“Proposal 1 — To elect the two Class I director nominees to hold office until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified. Each of the two nominees was so elected, with the votes thereon as follows: Final Voting Results Nominee For Withheld Broker Non-Votes Dinesh V. Patel, Ph.D. 48,714,702 7,875,311 2,819,234 Lewis T. “Rusty” Williams, M.D., Ph.D. 45,371,193 11,218,820 2,819,234”

SLM Corp shareholders approved Ratification of the Appointment of KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026 at the 2026-06-16 meeting.

“Proposal 3 – Ratification of the Appointment of KPMG LLP . The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. For Against Abstain Broker Non-Votes 177,679,238 1,027,672 178,920”

SLM Corp shareholders approved Advisory Vote on Executive Compensation at the 2026-06-16 meeting.

“Proposal 2 – Advisory Vote on Executive Compensation. The Company’s stockholders approved, by an advisory vote, the compensation of its named executive officers. For Against Abstain Broker Non-Votes 170,670,199 935,936 147,872 7,131,823”

SLM Corp shareholders approved Election of 13 directors for a one-year term at the 2026-06-16 meeting.

“Proposal 1 – Election of Directors. The Company’s stockholders elected the following 13 directors, each for a one-year term, to serve until their successors have been duly elected or appointed. For Against Abstain Broker Non-Votes Janaki Akella 163,005,066 8,635,493 113,448 7,131,823 R. Scott Blackley 171,316,912 322,872 114,223 7,131,823 Mary Carter Warren Franke 170,207,121 1,428,200 118,686 7,131,823 Daniel Greenstein 171,310,860 330,607 112,540 7,131,823 Henry F. Greig 171,319,278 321,341 113,388 7,131,823 Mark L. Lavelle 170,407,798 1,233,673 112,536 7,131,823 Christopher T. Leech 171,308,247 333,210 112,550 7,131,823 Ted Manvitz 171,309,412 330,953 113,642 7,131,823 Jim Matheson 164,941,960 6,693,275 118,772 7,131,823 Gary Millerchip 171,317,365 323,463 113,179 7,131,823 Vivian C. Schneck-Last 170,309,431 1,325,629 118,947 7,131,823 Jonathan W. Witter 171,306,613 333,370 114,024 7,131,823 Kirsten O. Wolberg 170,692,848 927,053 134,106 7,131,823”

MANHATTAN BRIDGE CAPITAL, INC shareholders approved Advisory approval of the appointment of Hoberman & Lesser, LLP as the Company’s independent auditors for the fiscal year ending December 31, 2026. at the 2026-06-18 meeting.

“Proposal No. 2 — Advisory approval of the appointment of Hoberman & Lesser, LLP as the Company’s independent auditors for the fiscal year ending December 31, 2026. For Against Abstain Broker Non-Votes 8,255,336 79,715 103,252 -”

MANHATTAN BRIDGE CAPITAL, INC shareholders approved Election of Directors at the 2026-06-18 meeting.

“Proposal No. 1 — Election of Directors Director Name For Withheld Broker Non-Votes Assaf Ran 4,885,937 212,928 3,339,438 Lyron Bentovim 4,878,098 220,767 3,339,438 Eran Goldshmit 4,831,640 267,225 3,339,438 Michael Jackson 4,860,703 238,162 3,339,438 Vanessa Kao 4,859,244 239,621 3,339,438 Phillip Michals 4,890,307 208,558 3,339,438”

Hercules Capital, Inc. shareholders approved Ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 at the 2026-06-18 meeting.

“Proposal 6. Ratify the appointment of PricewaterhouseCoopers LLP”

Hercules Capital, Inc. shareholders approved Approve the amendment and restatement of the Hercules Capital, Inc. 2018 Non-Employee Director Plan at the 2026-06-18 meeting.

“Proposal 5. Approve the amendment and restatement of the Hercules Capital, Inc. 2018 Non-Employee Director Plan”

Hercules Capital, Inc. shareholders approved Approve the amendment and restatement of the Hercules Capital, Inc. Amended and Restated 2018 Equity Incentive Plan at the 2026-06-18 meeting.

“Proposal 4. Approve the amendment and restatement of the Hercules Capital, Inc. Amended and Restated 2018 Equity Incentive Plan”

Hercules Capital, Inc. shareholders approved Advisory vote on the frequency of the advisory vote on executive compensation - 1 Year selected at the 2026-06-18 meeting.

“Proposal 3. Advisory vote on the frequency of the advisory vote on executive compensation”

Hercules Capital, Inc. shareholders approved Advisory vote to approve the Company’s named executive officer compensation at the 2026-06-18 meeting.

“Proposal 2. Advisory vote to approve the Company’s named executive officer compensation”

Hercules Capital, Inc. shareholders approved Election of one independent director - Robert P. Badavas at the 2026-06-18 meeting.

“Proposal 1. Election of one independent director”

SELLAS Life Sciences Group, Inc. shareholders approved Adjournment of the Annual Meeting to solicit additional proxies if necessary at the 2026-06-16 meeting.

“The Company’s stockholders approved an adjournment of the Annual Meeting, if necessary, to solicit additional proxies in favor of proposals 1, 2, 3 and 4.”

SELLAS Life Sciences Group, Inc. shareholders approved Non-binding advisory resolution on executive compensation at the 2026-06-16 meeting.

“The Company’s stockholders approved the non-binding, advisory resolution on the executive compensation of the Company’s named executive officers.”

SELLAS Life Sciences Group, Inc. shareholders approved Amendment to 2023 Amended and Restated Equity Incentive Plan to increase shares available by 20,000,000 at the 2026-06-16 meeting.

“The Company’s stockholders approved an amendment to the Company’s 2023 Amended and Restated Equity Incentive Plan (the “2023 Equity Plan”) to increase the number of shares of common stock available for sale under the 2023 Equity Plan by 20,000,000.”

SELLAS Life Sciences Group, Inc. shareholders approved Ratification of Baker Tilly US, LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-16 meeting.

“The Company’s stockholders ratified the appointment of Baker Tilly US, LLP (as the successor to Moss Adams LLP) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”

SELLAS Life Sciences Group, Inc. shareholders approved Election of Class I Directors at the 2026-06-16 meeting.

“The Company’s stockholders re-elected each of the following nominees as a Class I director to the Board of the Company to hold office until the 2029 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified.”

Nuvalent, Inc. shareholders approved Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-16 meeting.

“Proposal No. 3 — The appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified, based on the following votes: For Against Abstain Broker Non-Votes 71,172,889 858 17,147 —”

Nuvalent, Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2026-06-16 meeting.

“Proposal No. 2 — The compensation paid to the Company’s named executive officers was approved, on an advisory basis, based on the following votes: For Against Abstain Broker Non-Votes 68,898,711 1,786,465 17,926 487,792”

Nuvalent, Inc. shareholders approved Election of Class II directors at the 2026-06-16 meeting.

“Proposal No. 1 — The following nominees were elected as Class II directors, each to serve on the Board for a three-year term expiring at the 2029 annual meeting of stockholders and until their respective successors have been duly elected and qualified, based on the following votes: Nominee For Withheld Broker Non-Votes Michael L. Meyers, M.D., Ph.D. 57,592,636 13,110,466 487,792 Ron Squarer 70,612,828 90,274 487,792”

Oncology Institute, Inc. shareholders approved Approval, on a non-binding, advisory basis, of the preferred frequency of future advisory votes on the compensation of the Company’s named executive officers (the “Say-on-Frequency Proposal”) at the 2026-06-17 meeting.

“The Say-on-Frequency Proposal was approved”

Oncology Institute, Inc. shareholders approved Approval, on a non-binding, advisory basis, of the Company’s named executive officers (the “Say-on-Pay Proposal”) at the 2026-06-17 meeting.

“The Say-on-Pay Proposal was approved.”

Oncology Institute, Inc. shareholders approved Ratification of the Appointment of Independent Registered Public Accountants at the 2026-06-17 meeting.

“The ratification of the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved.”

Oncology Institute, Inc. shareholders approved Election of eight directors at the 2026-06-17 meeting.

“The Company’s stockholders elected eight directors to serve for the ensuing year and until their successors are elected and qualified, or until their earlier death, resignation or removal.”

STANDARD BIOTOOLS INC. shareholders approved Approval of the Amendment to the Amended and Restated 2017 Employee Stock Purchase Plan at the 2026-04-24 meeting.

“Approval of the Amendment to the Amended and Restated 2017 Employee Stock Purchase Plan. The proposal to approve the amendment to the ESPP to increase the shares of common stock reserved thereunder by 1,200,000 shares was approved by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 237,474,844 12,276,507 30,247 86,119,046”

STANDARD BIOTOOLS INC. shareholders approved Approval of the 2026 Equity Incentive Plan at the 2026-04-24 meeting.

“Approval of the 2026 Equity Incentive Plan. The proposal to approve the 2026 Plan was approved by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 228,342,854 17,821,911 3,616,833 86,119,046”

STANDARD BIOTOOLS INC. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-04-24 meeting.

“Ratification of Appointment of Independent Registered Public Accounting Firm. The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 was approved by the following vote: Votes For Votes Against Abstentions 330,172,606 652,236 5,075,802”

STANDARD BIOTOOLS INC. shareholders approved Advisory Vote on Approval of Executive Compensation at the 2026-04-24 meeting.

“Advisory Vote on Approval of Executive Compensation. The proposal to approve, on an advisory basis, the compensation of the Company’s named executive officers for the year ended December 31, 2025 was approved by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 209,778,412 36,318,595 3,684,591 86,119,046”

STANDARD BIOTOOLS INC. shareholders approved Election of Class I Directors at the 2026-04-24 meeting.

“Election of Class I Directors. The following nominees were elected to serve as Class I directors, to hold office until the Company’s 2029 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified or their earlier resignation or removal: Nominee Votes For Votes Withheld Broker Non-Votes Michael Egholm, Ph.D. 236,313,971 13,467,627 86,119,046 Thomas Carey 227,843,498 21,938,100 86,119,046 Eli Casdin 234,717,465 15,064,133 86,119,046”

PJT Partners Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for 2026 at the 2026-06-18 meeting.

“Proposal 3. To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for 2026: FOR AGAINST ABSTAIN BROKER NON-VOTES 37,397,361 472,022 9,980 N/A”

PJT Partners Inc. shareholders approved Advisory vote to approve compensation of Named Executive Officers at the 2026-06-18 meeting.

“Proposal 2. To approve, on an advisory basis, the compensation of our Named Executive Officers: FOR AGAINST ABSTAIN BROKER NON-VOTES 32,351,133 608,777 16,189 4,903,264”

PJT Partners Inc. shareholders approved Election of Directors at the 2026-06-18 meeting.

“Proposal 1. To elect the following Directors to the Board of Directors of the Company: Nominee FOR WITHHOLD BROKER NON-VOTES K. Don Cornwell 27,984,629 640,268 4,903,264 Peter L.S. Currie 28,562,472 62,425 4,903,264 Thomas M. Ryan 24,221,733 4,403,164 4,903,264”

OmniAb, Inc. shareholders approved Ratification of Ernst & Young LLP as independent auditor at the 2026-06-17 meeting.

“The appointment was ratified by the votes indicated: For Against Abstain Broker Non-Votes 102,163,551 112,653 135,380 0”

OmniAb, Inc. shareholders approved Election of two Class I directors at the 2026-06-17 meeting.

“The following two Class I directors were elected by the votes indicated: For Withheld Broker Non-Votes Jennifer Cochran, Ph.D. 57,948,696 25,997,984 18,464,904 Matthew W. Foehr 82,231,849 1,714,831 18,464,904”

Editas Medicine, Inc. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent auditor at the 2026-06-17 meeting.

“The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the stockholders’ vote with respect to such ratification were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 64,686,839 774,471 392,610 0”

Editas Medicine, Inc. shareholders approved Advisory vote on executive compensation at the 2026-06-17 meeting.

“The Company’s stockholders approved, on an advisory basis, the compensation paid to its named executive officers. The results of the stockholders’ non-binding, advisory vote with respect to compensation paid to the Company’s named executive officers were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 32,914,258 6,322,885 212,587 26,404,190”